Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Cancer Research: Curations and Reporting: Aviva Lev-Ari, PhD, RN

 

General

 

Lev-Ari, A. 7/5/2013, “2013 Perspective on “War on Cancer” on December 23, 1971

https://pharmaceuticalintelligence.com/2013/07/05/2013-perspective-on-war-on-cancer-on-december-23-1971/

Lev-Ari, A. 3/24/2013, New Ecosystem of Cancer Research: Cross Institutional Team Science

https://pharmaceuticalintelligence.com/2013/03/24/new-ecosystem-of-cancer-research-cross-institutional-team-science/

Lev-Ari, A. 7/25/2013, Family History of Cancer may increase the Risk of Close Relatives developing the Same Type of Cancer as well as Different Types

https://pharmaceuticalintelligence.com/2013/07/25/family-history-of-cancer-may-increase-the-risk-of-close-relatives-developing-the-same-type-of-cancer-as-well-as-different-types/

Lev-Ari, A. 4/12/2013, 2013 American Cancer Research Association Award for Outstanding Achievement in Chemistry in Cancer Research: Professor Alexander Levitzki

https://pharmaceuticalintelligence.com/2013/04/12/2013-american-cancer-research-association-award-for-outstanding-achievement-in-chemistry-in-cancer-research-professor-alexander-levitzki-chosen/

Lev-Ari, A. 6/12/2013, Bioenergetic Mechanism: The Inverse Association of Cancer and Alzheimer’s

https://pharmaceuticalintelligence.com/2013/06/12/bioenergetic-mechanism-the-inverse-association-of-cancer-and-alzheimers/

Lev-Ari, A. 1/12/2013, “Harnessing Personalized Medicine for Cancer Management, Prospects of Prevention and Cure: Opinions of Cancer Scientific Leaders @ http://pharmaceuticalintelligence.com“

https://pharmaceuticalintelligence.com/2013/01/12/harnessing-personalized-medicine-for-cancer-management-prospects-of-prevention-and-cure-opinions-of-cancer-scientific-leaders-httppharmaceuticalintelligence-com/

Lev-Ari, A. 12/1/2012, Personalized Medicine: Cancer Cell Biology and Minimally Invasive Surgery (MIS)

https://pharmaceuticalintelligence.com/2012/12/01/personalized-medicine-cancer-cell-biology-and-minimally-invasive-surgery-mis/

Lev-Ari, A. 4/8/2013, Amiodarone Linked to Cancer Risk in Men

https://pharmaceuticalintelligence.com/2013/04/08/amiodarone-linked-to-cancer-risk-in-men/

 

Reporting

New Biomarker for Esophageal Cancer Reported in the Journal “Cancer Research”

https://pharmaceuticalintelligence.com/2014/01/22/new-biomarker-for-esophageal-cancer-reported-in-the-journal-cancer-research/

Artificial Pancreas: A UK Biotech Invention – Potential for Replacement to Insulin Injections

https://pharmaceuticalintelligence.com/2014/01/27/artificial-pancreas-a-uk-biotech-invention-potential-for-replacement-to-insulin-injections/

Positron Emission Tomography (PET) and Near-Infrared Fluorescence Imaging:  Noninvasive Imaging of Cancer Stem Cells (CSCs)  monitoring of AC133+ glioblastoma in subcutaneous and intracerebral xenograft tumors

https://pharmaceuticalintelligence.com/2014/01/29/positron-emission-tomography-pet-and-near-infrared-fluorescence-imaging-noninvasive-imaging-of-cancer-stem-cells-cscs-monitoring-of-ac133-glioblastoma-in-subcutaneous-and-intracerebral-xenogra/

Efficacy of Ovariectomy in Presence of BRCA1 vs BRCA2 and the Risk for Ovarian Cancer

https://pharmaceuticalintelligence.com/2014/02/25/efficacy-of-ovariectomy-in-presence-of-brca1-vs-brca2-and-the-risk-for-ovarian-cancer/

Oncologists ordered 3,752 FoundationOne clinical test: 200 cancer-related genes analysis — Revenues Climb 87% in Q4 2013

https://pharmaceuticalintelligence.com/2014/02/26/oncologists-ordered-3752-foundationone-clinical-test-200-cancer-related-genes-analysis-revenues-climb-87-in-q4-2013/

Alternative to Imaging (potentially): Urine Test developed by MIT – A Paper Diagnostics amplifies Signals from Growing Tumors to detect Cancer

https://pharmaceuticalintelligence.com/2014/03/03/alternative-to-imaging-potentially-urine-test-developed-by-mit-a-paper-diagnostics-amplifies-signals-from-growing-tumors-to-detect-cancer/

Gene Therapy and the Genetic Study of Disease: @Berkeley and @UCSF – New DNA-editing technology spawns bold UC initiative as Crispr Goes Global

https://pharmaceuticalintelligence.com/2014/03/27/gene-therapy-and-the-genetic-study-of-disease-berkeley-and-ucsf-new-dna-editing-technology-spawns-bold-uc-initiative-as-crispr-goes-global/

Alterations in the ACVR1 Gene can contribute to a Rare, typically Fatal Form of Childhood Brainstem Cancer called Diffuse Intrinsic Pontine Glioma (DIPG).

https://pharmaceuticalintelligence.com/2014/04/10/alterations-in-the-acvr1-gene-can-contribute-to-a-rare-typically-fatal-form-of-childhood-brainstem-cancer-called-diffuse-intrinsic-pontine-glioma-dipg/

Novel Therapies for Cancer

Lev-Ari, A. 5/16/2013, AT13148 – A Novel Oral Multi-AGC Kinase Inhibitor Has Potent Antitumor Activity

https://pharmaceuticalintelligence.com/2013/05/16/at13148-a-novel-oral-multi-agc-kinase-inhibitor-has-potent-antitumor-activity/

Lev-Ari, A. 4/22/2013, “System Pharmacology: Using CellMiner and the NCI-60 Cancerous Cell Lines: William Reinhold, PhD”

https://pharmaceuticalintelligence.com/2013/04/22/system-pharmacology-using-cellminer-and-the-nci-60-cancerous-cell-lines-william-reinhold-phd/

Lev-Ari, A. 2/10/2013, Global Burden of Cancer Treatment & Women Health: Market Access & Cost Concerns

https://pharmaceuticalintelligence.com/2013/02/10/global-burden-of-cancer-treatment-women-health-market-access-cost-concerns/

Lev-Ari, A. 11/21/2012, Response to Multiple Cancer Drugs through Regulation of TGF- Receptor Signaling: a MED12 Control

https://pharmaceuticalintelligence.com/2012/11/21/response-to-multiple-cancer-drugs-through-regulation-of-tgf-%CE%B2-receptor-signaling-a-med12-control/

Lev-Ari, A. 10/1/2012, “Increased risks of obesity and cancer, Decreased risk of type 2 diabetes: The role of Tumor-suppressor phosphatase and tensin homologue (PTEN)”

https://pharmaceuticalintelligence.com/2012/10/01/increased-risks-of-obesity-and-cancer-decreased-risk-of-type-2-diabetes-the-role-of-tumor-suppressor-phosphatase-and-tensin-homologue-pten/

Lev-Ari, A. 12/8/2012, Aspirin a Day Tied to Lower Cancer Mortality

https://pharmaceuticalintelligence.com/2012/08/11/1796/

Lev-Ari, A. 2/5/2013, Winning Over Cancer Progression: New Oncology Drugs to Suppress Passengers Mutations vs. Driver Mutations

https://pharmaceuticalintelligence.com/2013/02/05/winning-over-cancer-progression-new-oncology-drugs-to-suppress-driver-mutations-vs-passengers-mutations/

Lev-Ari, A. 4/22/2013, “Molecular Profiling in Cancer Immunotherapy: Debraj Guha Thakurta, PhD”

https://pharmaceuticalintelligence.com/2013/04/22/molecular-profiling-in-cancer-immunotherapy/

Lev-Ari, A. 5/16/2013, “Immunomodulatory Therapeutic Antibodies for Cancer, August 13-15, 2013 – Boston, MA – Final Agenda”

https://pharmaceuticalintelligence.com/2013/05/16/immunomodulatory-therapeutic-antibodies-for-cancer-august-13-15-2013-boston-ma-final-agenda/

Lev-Ari, A. 11/14/2012, GSK for Personalized Medicine using Cancer Drugs needs Alacris systems biology model to determine the in silico effect of the inhibitor in its “virtual clinical trial”

https://pharmaceuticalintelligence.com/2012/11/14/gsk-for-personalized-medicine-using-cancer-drugs-needs-alacris-systems-biology-model-to-determine-the-in-silico-effect-of-the-inhibitor-in-its-virtual-clinical-trial/

Lev-Ari, A. 10/16/2012, Personalized Pancreatic Cancer Treatment Option

https://pharmaceuticalintelligence.com/2012/10/16/personalized-pancreatic-cancer-treatment-option/

Lev-Ari, A. 7/10/12, Pfizer’s Kidney Cancer Drug Sutent Effectively caused REMISSION to Adult Acute Lymphoblastic Leukemia (ALL)

https://pharmaceuticalintelligence.com/2012/07/10/pfizers-kidney-cancer-drug-sutent-effectively-caused-remission-to-adult-acute-lymphoblastic-leukemia-all/

Lev-Ari, A. 7/9/2012, Sunitinib brings Adult Acute Lymphoblastic Leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade

https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/

Lev-Ari, A. 7/10/2012, REMISSION to Adult Acute Lymphoblastic Leukemia (ALL): Pfizer’s Sutent blocks FLT3 Gene Receptors

https://pharmaceuticalintelligence.com/2012/07/10/remission-to-adult-acute-lymphoblastic-leukemia-all-pfizers-sutent-blocks-flt3-gene-receptors/

Genomics and Cancer

Lev-Ari, A. 9/18/2012, Head and Neck Cancer Studies Suggest Alternative Markers More Prognostically Useful than HPV DNA Testing

https://pharmaceuticalintelligence.com/2012/09/18/head-and-neck-cancer-studies-suggest-alternative-markers-more-prognostically-useful-than-hpv-dna-testing/

Lev-Ari, A. 10/24/2012, Pancreatic cancer genomes: Axon guidance pathway genes – aberrations revealed

https://pharmaceuticalintelligence.com/2012/10/24/pancreatic-cancer-genomes-axon-guidance-pathway-genes-aberrations-revealed/

Lev-Ari, A. 10/24/2012, Biomarker tool development for Early Diagnosis of Pancreatic Cancer: Van Andel Institute and Emory University

https://pharmaceuticalintelligence.com/2012/10/24/biomarker-tool-development-for-early-diagnosis-of-pancreatic-cancer-van-andel-institute-and-emory-university/

Lev-Ari, A. 4/22/2013, “DNA Methultransferases – Implications to Epigenetic Regulation and Cancer Therapy Targeting: James Shen, PhD”

https://pharmaceuticalintelligence.com/2013/04/22/dna-methultransferases-implications-to-epigenetic-regulation-and-cancer-therapy-targeting-james-shen-phd/

Lev-Ari, A. 4/22/2013, “Genotype-based Analysis for Cancer Therapy using Large-scale Data Modeling: Nayoung Kim, PhD(c)”

https://pharmaceuticalintelligence.com/2013/04/22/genotype-based-analysis-for-cancer-therapy-using-large-scale-data-modeling-nayoung-kim-phdc/

Lev-Ari, A. 4/21/2013, Cancer Genomic Precision Therapy: Digitized Tumor’s Genome (WGSA) Compared with Genome-native Germ Line: Flash-frozen specimen and Formalin-fixed paraffin-embedded Specimen Needed

https://pharmaceuticalintelligence.com/2013/04/21/cancer-genomic-precision-therapy-digitized-tumors-genome-wgsa-compared-with-genome-native-germ-line-flash-frozen-specimen-and-formalin-fixed-paraffin-embedded-specimen-needed/

Lev-Ari, A. 1/13/2013, LEADERS in Genome Sequencing of Genetic Mutations for Therapeutic Drug Selection in Cancer Personalized Treatment: Part 2

https://pharmaceuticalintelligence.com/2013/01/13/leaders-in-genome-sequencing-of-genetic-mutations-for-therapeutic-drug-selection-in-cancer-personalized-treatment-part-2/

Lev-Ari, A. 1/10/2013, Inspiration From Dr. Maureen Cronin’s Achievements in Applying Genomic Sequencing to Cancer Diagnostics

https://pharmaceuticalintelligence.com/2013/01/10/inspiration-from-dr-maureen-cronins-achievements-in-applying-genomic-sequencing-to-cancer-diagnostics/

Lev-Ari, A. 11/1/2012, arrayMap: Genomic Feature Mining of Cancer Entities of Copy Number Abnormalities (CNAs) Data

https://pharmaceuticalintelligence.com/2012/11/01/arraymap-genomic-feature-mining-of-cancer-entities-of-copy-number-abnormalities-cnas-data/

Lev-Ari, A. 10/29/2012, Cancer Genomics – Leading the Way by Cancer Genomics Program at UC Santa Cruz

https://pharmaceuticalintelligence.com/2012/10/29/cancer-genomics-leading-the-way-by-cancer-genomics-program-at-uc-santa-cruz/

Lev-Ari, A. 9/10/2012, Comprehensive Genomic Characterization of Squamous Cell Lung Cancers

https://pharmaceuticalintelligence.com/2012/09/10/comprehensive-genomic-characterization-of-squamous-cell-lung-cancers/

Lev-Ari, A. 5/21/2013, “Prostate Cancer Molecular Diagnostic Market – the Players are: SRI Int’l, Genomic Health w/Cleveland Clinic, Myriad Genetics w/UCSF, GenomeDx and BioTheranostics”

https://pharmaceuticalintelligence.com/2013/05/21/prostate-cancer-molecular-diagnostic-market-the-players-are-sri-intl-genomic-health-wcleveland-clinic-myriad-genetics-wucsf-genomedx-and-biotheranostics/

Lev-Ari, A. 5/16/2013, “A Blood Test to Identify Aggressive Prostate Cancer: a Discovery @ SRI International, Menlo Park, CA”

https://pharmaceuticalintelligence.com/2013/05/16/a-blood-test-to-identify-aggressive-prostate-cancer-a-discovery-sri-international-menlo-park-ca/

Lev-Ari, A. 5/20/2013, Salivary Gland Cancer – Adenoid Cystic Carcinoma: Mutation Patterns: Exome- and Genome-Sequencing @ Memorial Sloan-Kettering Cancer Center

https://pharmaceuticalintelligence.com/2013/05/20/salivary-gland-cancer-adenoid-cystic-carcinoma-mutation-patterns-exome-and-genome-sequencing-memorial-sloan-kettering-cancer-center/

 

Cancer Research by Cancer Type

 

Breast

Lev-Ari, A. 7/3/2013, MIT Scientists Identified Gene that Controls Aggressiveness in Breast Cancer Cells

https://pharmaceuticalintelligence.com/2013/07/03/mit-scientists-identified-gene-that-controls-aggressiveness-in-breast-cancer-cells/

Lev-Ari, A. 4/23/2013, Tamoxifen’s Effectiveness: Decrease in Tissue Density by Mammography – 50% Lower Risk of Dying from Breast Cancer

https://pharmaceuticalintelligence.com/2013/04/23/tamoxifens-effectiveness-decrease-in-tissue-density-by-mammography-50-lower-risk-of-dying-from-breast-cancer/

Lev-Ari, A. 1/17/2013, Mechanism involved in Breast Cancer Cell Growth: Function in Early Detection & Treatment

https://pharmaceuticalintelligence.com/2013/01/17/mechanism-involved-in-breast-cancer-cell-growth-function-in-early-detection-treatment/

Lev-Ari, A. 8/14/2012, Missing Gene may drive more than a quarter of Breast Cancers

https://pharmaceuticalintelligence.com/2012/08/14/missing-gene-may-drive-more-than-a-quarter-of-breast-cancers/

Breast/Ovarian

Lev-Ari, A. 5/20/2013, “Testing for Multiple Genetic Mutations via NGS for Patients: Very Strong Family History of Breast & Ovarian Cancer, Diagnosed at Young Ages, & Negative on BRCA Test”           

https://pharmaceuticalintelligence.com/2013/05/20/testing-for-multiple-genetic-mutations-via-ngs-for-patients-very-strong-family-history-of-breast-ovarian-cancer-diagnosed-at-young-ages-negative-on-brca-test/

Breast/Personalized Medicine

Lev-Ari, A. 12/24/2014, Breast Cancer: Genomic profiling to predict Survival: Combination of Histopathology and Gene Expression Analysis

https://pharmaceuticalintelligence.com/2012/12/24/breast-cancer-genomic-profiling-to-predict-survival-combination-of-histopathology-and-gene-expression-analysis/

Colon

Lev-Ari, A. 11/28/2012, PIK3CA mutation in Colorectal Cancer may serve as a Predictive Molecular Biomarker for adjuvant Aspirin therapy

https://pharmaceuticalintelligence.com/2012/11/28/pik3ca-mutation-in-colorectal-cancer-may-serve-as-a-predictive-molecular-biomarker-for-adjuvant-aspirin-therapy/

Epigenetics

Lev-Ari, A. 4/12/2013, Critical Gene in Calcium Reabsorption: Variants in the KCNJ and SLC12A1 genes – Calcium Intake and Cancer Protection

https://pharmaceuticalintelligence.com/2013/04/12/critical-gene-in-calcium-reabsorption-variants-in-the-kcnj-and-slc12a1-genes-calcium-intake-and-cancer-protection/

Gastric

Lev-Ari, A. 10/17/2012, Stomach Cancer Subtypes Methylation-based identified by Singapore-Led Team           

https://pharmaceuticalintelligence.com/2012/10/17/stomach-cancer-subtypes-methylation-based-identified-by-singapore-led-team/

Gastric/Personalized Medicine

Lev-Ari, A. 12/24/2012, Gastric Cancer: Whole-genome reconstruction and mutational signatures

https://pharmaceuticalintelligence.com/2012/12/24/gastric-cancer-whole-genome-reconstruction-and-mutational-signatures-2/

Skin Cancer

Lev-Ari, A. 4/24/2013, Association between Non-melanoma Skin Cancer and subsequent Primary Cancers in White Population

https://pharmaceuticalintelligence.com/2013/04/24/association-between-non-melanoma-skin-cancer-and-subsequent-primary-cancers-in-white-population/

Prostate Cancer

Lev-Ari, A. 2/14/13, Prostate Cancer: Androgen-driven “Pathomechanism” in Early-onset Forms of the Disease

https://pharmaceuticalintelligence.com/2013/02/14/prostate-cancer-androgen-driven-pathomechanism-in-early-onset-forms-of-the-disease/

Lev-Ari, A. 7/31/2012, “Prostate Cancers Plunged After USPSTF Guidance, Will It Happen Again?”

https://pharmaceuticalintelligence.com/2012/07/31/prostate-cancers-plunged-after-uspstf-guidance-will-it-happen-again/

Head & Neck

Lev-Ari, A. 1030/2012, Acoustic Neuroma, Neurinoma or Vestibular Schwannoma: Treatment Options

https://pharmaceuticalintelligence.com/2012/10/30/acoustic-neuroma-neurinoma-or-vestibular-schwannoma-treatment-options/

Lev-Ari, A. 10/30/2012, Clinical Trials on Schwannoma & Benign Intracranial Tumors Radiosurgery Treatment

https://pharmaceuticalintelligence.com/2012/10/30/clinical-trials-on-schwannoma-benign-intracranial-tumors-radiosurgery-treatment/

Lev-Ari, A. 10/15/2012, Facial Nerve, Intracanalicular Meningiomas, Vestibular Schwannomas: Surgical Planning

https://pharmaceuticalintelligence.com/2012/10/15/facial-nerve-intracanalicular-meningiomas-vestibular-schwannomas-surgical-planning/

 

Cancer and the Human Heart – Correlation between Cancer and Cardiovascular Diseases

 

o     Causes

Lev-Ari, A. 1/8/2014, Reuben Shaw, Ph.D., a geneticist and researcher at the Salk Institute: Metabolism Influences Cancer

https://pharmaceuticalintelligence.com/2014/01/08/reuben-shaw-ph-d-a-geneticist-and-researcher-at-the-salk-institute-metabolism-influences-cancer/

Lev-Ari, A. 1/8/2014, Heart Tumors: Etiology and Classification

https://pharmaceuticalintelligence.com/2014/01/08/heart-tumors-etiology-and-classification/

 

o     Biomarkrs

Lev-Ari, A. 1/15/2014, Cancer Symptom Science: On the Mechanisms underlying the Expression of Cancer-related Symptoms

https://pharmaceuticalintelligence.com/2014/01/15/cancer-symptom-science-on-the-mechanisms-underlying-the-expression-of-cancer-related-symptoms/

o     Therapies

Lev-Ari, A. 1/8/2014, Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease

https://pharmaceuticalintelligence.com/2014/01/08/cardio-oncology-and-onco-cardiology-programs-treatments-for-cancer-patients-with-a-history-of-cardiovascular-disease/

Lev-Ari, A. 1/8/2014, Radiation and Chemotherapy Therapy: The Pharmacological Risk for Developing Cardiovascular Disease

https://pharmaceuticalintelligence.com/2014/01/08/20316/

Lev-Ari, A. 1/8/2014, 3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre

https://pharmaceuticalintelligence.com/2014/01/08/3rd-annual-canadian-cardiac-oncology-network-conference-june-20-21-2013-ottawa-convention-centre/